MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system
Authors:
- Marco GessiMGMarco Gessi
- André O. von BuerenABAndré O. von Bueren
- Andras TreszlATAndras Treszl
- Anja Zur MühlenAMAnja Zur Mühlen
- Wolfgang HartmannWHWolfgang Hartmann
- Monika Warmuth-MetzMWMonika Warmuth-Metz
- Stefan RutkowskiSRStefan Rutkowski
- Torsten PietschTPTorsten Pietsch
Open Access
- 26 January 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 16 (7) , 924-932
Abstract
Primitive neuroectodermal tumors of the central nervous system (CNS-PNETs) are a rare group of neoplasms occurring in the CNS that includes supratentorial CNS-PNETs, medulloepitheliomas, and ependymoblastomas. While ependymoblastomas frequently carry chromosome 19q13.41 amplification and show aggressive clinical behavior, the biological mechanisms and molecular alterations contributing to the pathogenesis of supratentorial CNS-PNETs remain poorly understood. Moreover, genetic alterations suitable for molecular risk stratification are undefined to date. In order to identify possible molecular markers, we performed multiplex ligation-dependent probe amplification (MLPA) and molecular inversion probe (MIP) analysis on DNA samples of 25 supratentorial CNS-PNETs (median age, 5.35 years; range, 2.41–17.28 years). Tumors with ependymoblastic rosettes (ependymoblastoma/ETANTR) and LIN28A positivity were excluded. MLPA and MIP analysis revealed large losses of genomic material of chromosomes 3, 4, 5, and 13, while frequent gains affected chromosomes 1, 17, 19, 20, and 22. High copy number gains (amplifications) were found in particular at chromosomes 2p24.3 (MYCN, n = 6 cases) and 4q12 (n = 2 cases). Patients with tumors harboring 2p gain or MYCN amplification showed unfavorable overall survival (P = .003 and P = .001, respectively).These markers were independent of the presence of metastases, which was indeed a clinical factor associated with poor overall survival (P = .01) in this series. In the era of the personalized neuro-oncology, the identification of these molecular prognostic markers associated with patient outcome may represent a significant step towards improved patient stratification and risk-adapted therapeutic strategies for patients suffering from supratentorial CNS-PNETs.Keywords
This publication has 35 references indexed in Scilit:
- DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysisJournal of Neuro-Oncology, 2012
- Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastomaNeuro-Oncology, 2011
- Central Nervous System Primitive Neuroectodermal Tumors: A Clinicopathologic and Genetic Study of 33 CasesBrain Pathology, 2010
- RASSF1A promoter is highly methylated in primitive neuroectodermal tumors of the central nervous systemNeuropathology, 2007
- Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomasGenes, Chromosomes and Cancer, 2007
- High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal TumorsJournal of Neuropathology & Experimental Neurology, 2006
- High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastomaHistopathology, 2006
- Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastomaNeurosurgical Focus, 2005
- Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour‐associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhoodNeuropathology and Applied Neurobiology, 2002
- Prediction of central nervous system embryonal tumour outcome based on gene expressionNature, 2002